Target intelligence / Profile preview

Hepatitis B virus envelope antigen (HBeAg)

Target
HBeAg
Molecular classification
Other
01

Overview

Hepatitis B virus envelope antigen (HBeAg), also known as Hepatitis B e antigen, is a nonparticulate, soluble viral protein encoded by the precore/core gene of the Hepatitis B virus (HBV). It is processed and secreted by infected hepatocytes into the bloodstream during active viral replication, serving as a key clinical marker for high infectivity and viral load. Biologically, HBeAg acts as an immunomodulator that downregulates host innate immune responses, such as Toll-like receptor 2 expression, thereby promoting immune tolerance and facilitating persistent, chronic HBV infection. In clinical practice, HBeAg seroconversion (the loss of HBeAg and appearance of anti-HBe antibodies) is a major therapeutic endpoint indicating transition to a less active phase of infection. While traditional therapies like nucleos(t)ide analogues (e.g., entecavir, tenofovir) and pegylated interferons indirectly reduce HBeAg levels by suppressing viral replication or boosting host immunity, novel therapeutic strategies are being developed to target HBeAg more directly. These include capsid assembly modulators (CpAMs) that cause misassembly of the precore protein to block HBeAg secretion, and RNA interference (RNAi) agents that degrade viral transcripts to silence HBeAg expression.

Other names
Hepatitis B e antigenHepatitis B virus e antigenHBV e antigenHBV envelope antigenExternal core antigenPrecore protein
02

Mechanism of action

Inhibition of viral replication and protein expression, leading to HBeAg seroconversion and reduction of viral load. Nucleos(t)ide analogues inhibit HBV DNA polymerase/reverse transcriptase, while pegylated interferons modulate the host immune response to suppress viral replication. Novel capsid assembly modulators (CpAMs) can directly bind to the precore/core protein, causing misassembly and preventing HBeAg secretion. RNA interference (RNAi) therapeutics like JNJ-3989 target HBV transcripts to degrade viral mRNA and inhibit HBeAg expression.

03

Biological functions

Immune responseOther
04

Disease associations

InfectionOther
05

Safety considerations

Risk of hepatitis flare or hepatic decompensation upon treatment discontinuation or drug resistanceDevelopment of drug-resistant HBV mutants (e.g., precore G1896A mutation which stops HBeAg production but allows active replication)Systemic side effects of interferon therapy (flu-like symptoms, depression, cytopenias)Renal toxicity and bone mineral density loss associated with certain nucleotide analogues (e.g., TDF)
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

HBeAg statusHBeAg quantitative levelsAnti-HBe antibodyHBV DNA viral loadHBsAg levelsAlanine aminotransferase (ALT)Hepatitis B core-related antigen (HBcrAg)

Beyond the preview

Go deeper on Hepatitis B virus envelope antigen (HBeAg).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis B virus envelope antigen (HBeAg).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call